Navigation Links
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
Date:9/3/2009

CHADDS FORD, Pa., Sept. 3 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks. VALSTAR represents a new treatment option for these patients who may otherwise have exhausted all other FDA-approved treatment alternatives, including BCG.

"Patients with recurrent carcinoma in situ bladder tumors who fail traditional therapy have been significantly underserved due to the lack of available approved treatment alternatives, and VALSTAR will provide a well-tolerated treatment option for these patients," said Dave Holveck, president and chief executive officer of Endo Pharmaceuticals. "Our launch of VALSTAR also represents our initial offering in a long-term plan by Endo to deliver multiple therapies to improve and extend the lives of patients with different types of bladder cancer, as evidenced by our recent agreement with Bioniche."

VALSTAR, a sterile solution for intravesical instillation of valrubicin, is placed directly into the bladder through a catheter and is administered once a week for six weeks under the supervision of a physician experienced in the use of intravesical cancer chemotherapeutic agents.

In the pivotal clinical trial, VALSTAR was shown to induce a complete response in about one in five patients at six months following initiation of therapy, and 29 percent of patients derived a clinical benefit from VALSTAR treatment. It is important to note that if after VALSTAR trea
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
2. Isis Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
3. Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism
4. DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
6. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
7. Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference
8. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
9. Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009
10. Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
11. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 ResortQuest Real Estate® is proud ... Feher team at the firm’s Bethany Beach location. , ... her home in 1975. Her real estate career began ... aspects of the real estate business - receptionist, cleaning ... years, a licensed sales associate. , “I am ...
(Date:5/24/2013)... New research suggests a link between sleep duration ... Every additional hour someone with insomnia sleeps is ... likelihood of moderate or high risk of suicide, ... "We were surprised by the strength ... risk," study author, Linden Oliver, clinical research coordinator ...
(Date:5/24/2013)... used to treat glaucoma may cause droopy eyelids and ... to a new study. The drugs, known as ... pressure, have already been shown to cause blurred vision, ... suggesting that the new findings could lead to labeling ... when prescribing these drugs, the researchers added, particularly as ...
(Date:5/24/2013)... CA (PRWEB) May 24, 2013 Area homeowners ... selection of new hot tubs to choose from at factory-direct ... Sale . The sales event takes place at Emerald ... 26, 2013. , Jacuzzi, the industry's leading hot tub ... traveling across the country. The event will feature popular hot ...
(Date:5/24/2013)... mutations central to the development of infantile myofibromatosis (IM)a ... and soft tissuemay provide new therapeutic targets, according to ... Sinai. The findings, published in the American Journal ... options for this debilitating disease, for which the only ... tumors. , IM is an inheritied disorder that develops ...
Breaking Medicine News(10 mins):Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2
... Del., Nov. 2 Staff and board,members of Delaware ... Lloyd, MSN, RN, for 20 years of service at ... has guided Delaware Hospice from a fledgling,grassroots organization to ... community support with quality and compassion., In 1987, ...
... Barr,Pharmaceuticals, Inc. (NYSE: BRL ) today confirmed ... challenge of the patents listed by,Novartis Pharmaceuticals Corporation ... capsules, 10mg, 20mg, 30mg,and 40mg. Barr filed ... IV certification for a generic Ritalin LA product ...
... SOUTH PORTLAND, Maine, Nov. 2 Small employers ... much larger businesses. Anthem,Blue Cross and Blue Shield ... for small businesses (50 or fewer employees) under ... health insurance,choices than have ever been available for ...
... Urology; Initiated for ... Dermatology and OB/GYN, ... force in measuring the impact of pharmaceutical promotion on,physicians, prescribing ... networks in alignment with emerging market,trends and rising client demand. ...
... Mass., Nov. 2 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... President, and CEO, will present a corporate,overview at The ... New York City on Monday, November 5, 2007 at ... The New York Palace Hotel, New York,City. The Company,s ...
... PXS; Nasdaq: PXSL) today announced moves to expand its ... construction of a new,state of the art facility at ... the fourth quarter of 2008,Pharmaxis may lease the 7,000 ... 15 years with two options to renew of five ...
Cached Medicine News:Health News:Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN 2Health News:Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN 3Health News:Barr Confirms Patent Challenge of Ritalin(R) LA 2Health News:Barr Confirms Patent Challenge of Ritalin(R) LA 3Health News:Anthem Introduces New Insurance Options for Small Business 2Health News:ImpactRx Announces Expansion and Addition of Physician Information Networks 2Health News:ImpactRx Announces Expansion and Addition of Physician Information Networks 3Health News:Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th 2Health News:Pharmaxis to Expand Manufacturing Capacity 2
(Date:5/24/2013)... /PRNewswire-iReach/ -- Phoenix Houses of California ... is hosting its tenth annual "Triumph For Teens" Awards ... 2013.  More than 300 people are expected to attend ... treatment centers, family therapy, and prevention programs of Phoenix ... positive influences on the health and welfare of our community ...
(Date:5/24/2013)... , May 24, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" ... specialty products, announced today that Dr. Robert Grieve ... Jason Napolitano , executive vice president and ... MicroCap Conference, which is being held May 30, 2013 in ... Hyatt Hotel. The Company,s presentation is scheduled ...
(Date:5/24/2013)... 24, 2013 In accordance with Rule 17.1 and ... of the United States Exchange Act, Echo Pharma Acquisition Limited ... Elan Corporation (NYSE: ELN). Background On ... an offer for the entire of the issued and to ... "Original Offer").  On 20 May 2013, Royalty ...
Breaking Medicine Technology:Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
The 5524-7.5 linear transducer is a high frequency transducer dedicated to superficial and vascular imaging....
The 5539-7.5 linear transducer is a high frequency transducer dedicated to superficial and vascular imaging....
HST, versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Scan internal organs percutaneously while eliminating side lobe artifact....
Medicine Products: